摘要
Background: Cancer-testis antigens(CTAs) as targets for immunotherapy and prognostic markers have been studied in cancer patients. MAGE-A4 and NY-ESO-1 were well-known CTAs as attractive targets for immunotherapy and prognosis in multiple cancers. The Objective of this study was to analyze extent and prognostic significance of MAGE-A4 and NY-ESO-1 expression in non-small cell lung cancer(NSCLC). Methods: One hundred and ninety-six fresh NSCLC surgical resections were collected as diagnostic specimens from patients treated at the First Afflicted Hospital of Zhengzhou University from 2014.11-2015.12. Here we analyzed theexpression of HLA-A2 by Flow Cytometry. The expression of MAGE-A4 and NY-ESO-1 were detected by RT-PCR usingfreshly resected cancer tissues from patients with NSCLC.We evaluated the association of their expression with clinical pathological features and survival. Results:The mRNA expression of MAGE-A4 and NY-ESO-1 were detectedin 82/196(41.8%) and 31/196(15.8%) of NSCLCs. 93/196(47.4%) patients expressed at least one of both CTAs, while both CTAs were positivein 22/196(11.2%).MAGE-A4 expression was associated with age, smoking history and disease stage(P<0.05). NY-ESO-1 expression was related to age, squamous carcinoma, poorly differentiated and advanced stage(P<0.05). In addition, Co-expression of both CTAs washigher in advanced disease stage and less than 65 years old group(P<0.05). CTAs positive patients showed poorer survival than CTAs negative patients(P<0.05).Conclusion: CTA expression was significantly associated with prognostic factors of pooroutcome of disease(advanced tumor stage and lymph node metastasis). MAGE-A4 is identified as a specific biomarker of NSCLC, with a possible oncogenic role contributing to tumor progression and associated with poor outcome. CTAs are potential candidates in NSCLC patients for immunotherapy such as multiple antigen vaccine therapy and specific modified T cell receptor gene therapy.
Background: Cancer-testis antigens(CTAs) as targets for immunotherapy and prognostic markers have been studied in cancer patients. MAGE-A4 and NY-ESO-1 were well-known CTAs as attractive targets for immunotherapy and prognosis in multiple cancers. The Objective of this study was to analyze extent and prognostic significance of MAGE-A4 and NY-ESO-1 expression in non-small cell lung cancer(NSCLC). Methods: One hundred and ninety-six fresh NSCLC surgical resections were collected as diagnostic specimens from patients treated at the First Afflicted Hospital of Zhengzhou University from 2014.11-2015.12. Here we analyzed theexpression of HLA-A2 by Flow Cytometry. The expression of MAGE-A4 and NY-ESO-1 were detected by RT-PCR usingfreshly resected cancer tissues from patients with NSCLC.We evaluated the association of their expression with clinical pathological features and survival. Results:The mRNA expression of MAGE-A4 and NY-ESO-1 were detectedin 82/196(41.8%) and 31/196(15.8%) of NSCLCs. 93/196(47.4%) patients expressed at least one of both CTAs, while both CTAs were positivein 22/196(11.2%).MAGE-A4 expression was associated with age, smoking history and disease stage(P<0.05). NY-ESO-1 expression was related to age, squamous carcinoma, poorly differentiated and advanced stage(P<0.05). In addition, Co-expression of both CTAs washigher in advanced disease stage and less than 65 years old group(P<0.05). CTAs positive patients showed poorer survival than CTAs negative patients(P<0.05).Conclusion: CTA expression was significantly associated with prognostic factors of pooroutcome of disease(advanced tumor stage and lymph node metastasis). MAGE-A4 is identified as a specific biomarker of NSCLC, with a possible oncogenic role contributing to tumor progression and associated with poor outcome. CTAs are potential candidates in NSCLC patients for immunotherapy such as multiple antigen vaccine therapy and specific modified T cell receptor gene therapy.
引文